

# europaean journal of gynaecological oncology

an International Journal

*Editors-in-Chief*

**A. Onnis** **P. Bószé**  
Montréal (Canada) Budapest (Hungary)

*Associate Editor*

**M. Marchetti**  
Montréal (Canada)

*Assistant Editor*

**J. Wilson**  
San Diego - CA (USA)

*Editorial Board*

Allen H.H., London, Ontario (Canada)	Geisler H.E., Indianapolis, IN (USA)	Monsonogo J., Paris (France)
Anteby S.O., Jerusalem (Israel)	Gerbaulet A., Villejuif (France)	Pálfalvi L., Budapest, (Hungary)
Audet-Lapointe P., Montreal (Canada)	Gorins A., Paris (France)	Pinotti A., São Paulo (Brazil)
Ayhan A., Ankara (Turkey)	Heintz A.P.M., Utrecht (The Netherlands)	Piura B., Beer Sheva (Israel)
Balat O., Graziantep (Turkey)	Ioannidou-Mouzaka L., Athens (Greece)	Piver S.M., Buffalo, NY (USA)
Barber H.K., New York, NY (USA)	Jordan J.A., Birmingham, England (UK)	Rakar S., Ljubljana (Slovenia)
Basta A., Krakow (Poland)	Karseladze A.I., Moscow (Russia)	Raju K.S., London, England (UK)
Bender H.C., Dusseldorf (Germany)	Klastersky J., Bruxelles (Belgium)	Shepherd J.H., London, England (UK)
Benedetti Panici P.L., Rome (Italy)	Kubista E., Vienna (Austria)	Stelmachów J., Warsaw (Poland)
Charkviani T., Tbilisi (Georgia)	Kudelka A.P., Houston, TX (USA)	Tjalma W., Antwerpen (Belgium)
De Oliveira C.F., Coimbra (Portugal)	Maggino T., Padua (Italy)	Ungár L., Budapest (Hungary)
Dexeus S. Jr., Barcelona (Spain)	Markowska J., Poznan (Poland)	Vermorken J.B., Edegem (Belgium)
Di Paola G.R., Buenos Aires (Argentina)	Marth C., Innsbruck (Austria)	Vîrtej P., Bucharest (Romania)
Di Re F., Milan (Italy)	Massuger Leon F.A.G., Nijmegen (The Netherlands)	Wang P.-H., Taipei (Taiwan)
Di Saia P., Orange, CA (USA)	Menczer J., Savyon (Israel)	Winter R., Graz (Austria)
Friedrich M., Hamburg (Germany)		Yokoyama Y., Hirosaki (Japan)
Fuller A.F. Jr., Boston, MA (USA)		

*Publishing Organization (M. Morsani):*

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)  
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

*Editorial Office (M. Critelli):*

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

# European Journal of Gynaecological Oncology

www.irog.net

## General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

### AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

**ANNOUNCEMENTS** regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

**BOOK SAMPLES** for review should be sent to the Editorial offices in Montréal or in Padova.

**COPYRIGHT:** the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

**ADVERTISING INFORMATION:** advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H5, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mgroup-online.com - www.irog.net

**RESPONSIBILITY:** although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

### SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

**Subscriptions are entered with prepayment only.** The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

**Claims** for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

# European Journal of Gynaecological Oncology

www.irog.net

## Instructions to Authors

### SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

**Publication time will be the shortest possible** based on scientific and publishing needs. **Manuscripts submitted for publication cannot be returned.**

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

### MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts* typed and double spaced should be submitted by mail (not by email) **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0.** Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (*purpose of investigation, methods, results, conclusion - about 150 words*), **Key words**, **Content** (a 20-word summary), **Introduction**, **Materials and Methods**, **Results**, **Discussion**, **Conclusion**, **Acknowledgement** (if any), **References**, **Tables**, **Legends**.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

**Authors** must give their complete professional identifications and affiliations, including all academic titles and positions.

**Letters to the editor** should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

**Figures:** Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

**Legends** should be typed on a separate page with Arabic numerals corresponding to the illustrations.

**Tables** should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

**References should be numbered consecutively in the order in which they are first mentioned in the text.** Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

**Articles in Journals:** Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

**Books:** Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

**Acknowledgments** will be limited to appropriate professionals who were contributors to the paper.

**PROOFS** revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved.** Only essential corrections should be made; extensive changes will be charged to the authors.

### BUSINESS MATTERS

The Journal has no commercial advertisements.

**Authors will be expected to contribute to the printing expenses, tables, figures and postage.** For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

**Reprints** should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

## DISTINGUISHED EXPERT SERIES

- Molecular markers of miscellaneous primary and metastatic tumors of the uterine cervix** 5  
 S.C. Chauhan, D. Kumar, M.C. Bell, M.D. Koch, M. Verma - *Bethesda, MD, USA*  
 Strategies to discover novel molecular markers for miscellaneous primary tumors of the uterine cervix were studied.

## ORIGINAL ARTICLES

- Giving patients information on abnormal cytology and human papillomavirus: Survey of health providers** 15  
 M. Howard, J. Koteles, A. Lytwyn, L. Elit, J. Kaczorowski, J. Randazzo - *Ontario, CANADA*  
 Health providers have moderate comfort regarding their knowledge level in answering women's questions about human papillomavirus.
- Immunoreactivities of human nonmetastatic clone 23 and p53 products are disassociated and not good predictors of lymph node metastases in early-stage cervical cancer patients** 18  
 Y.T. Tee, P.H. Wang, J.L. Ko, G.D. Chen, H. Chang, L.Y. Lin - *Taichung, TAIWAN*  
 nm23-H1 and p53 do not show significant associations with lymph node metastases in early-stage cervical cancer.
- Survival of 231 cervical cancer patients, treated by radical hysterectomy, according to clinical and histopathological features** 23  
 K. Lukaszuk, J. Liss, M. Nowaczyk, W. Sliwinski, B. Maj, I. Wozniak, M. Nakonieczny, D. Barwinska - *Gdańsk, POLAND*  
 Clinical data and histopathological parameters of 231 patients with invasive cervical carcinoma treated in gynecology centers were correlated with survival.
- Prognostic factors affecting disease-free survival in early-stage cervical cancer patients undergoing radical hysterectomy and pelvic-paraortic lymphadenectomy** 28  
 J. Metindir, G. Bilir - *Çankaya/Ankara, TURKEY*  
 Surgical and histopathologic prognostic factors that predicted 5-year disease-free survival (DFS) after patients underwent radical hysterectomy and pelvic, paraortic lymphadenectomy for FIGO Stage I-II cervical carcinoma were studied.
- Supraclavicular lymph node metastasis in cervical cancer** 33  
 J. Qiu, K.C. Ho, C. Huey Lai, T.C. Yen, Y.T. Huang, A. Chao, T.C. Chang - *Taoyuan, TAIWAN*  
 Cervical cancer patients with supraclavicular node metastasis at primary diagnosis are not invariably fatal. Providing curative treatment to selected patients is justified.
- Evaluation of abnormal uterine bleeding by transvaginal 3-D hysterosonography and diagnostic hysteroscopy** 39  
 N. Makris, N. Skartados, K. Kalmantis, G. Mantzaris, A. Papadimitriou, A. Antsaklis - *Athens, GREECE*  
 Although 3-dimensional (3-D) hysterosonography enables accurate detection of intrauterine pathology comparable to hysteroscopy, multicenter studies are required to confirm the value of 3-D hysterosonography.
- Presumed Stage IA primary epithelial ovarian carcinoma: the role of complete staging surgery** 43  
 H.C. Horng, C.C. Yuan, C.R. Lai, P.H. Wang - *Taipei, TAIWAN*  
 Carefully-selected presumed Stage IA primary epithelial ovarian carcinoma cases could be closely followed-up without restaging surgery.
- Serum CA-125 is a good predictor of benign disease in patients with postmenopausal ovarian cysts** 45  
 E. Dikensoy, O. Balat, M.G. Ugur, A. Ozkur, S. Erkilic - *Gaziantep, TURKEY*  
 Serum CA-125 is a very good predictor of benign disease in patients with postmenopausal ovarian cysts.
- Survival and prognostic factors of patients treated for Stage I to Stage III endometrial carcinoma in a reference cancer center in Southern Brazil** 48  
 S.A. Pessini, C.G. Zettler, M.C.O. Wender, L.C. Pellanda, G.P.G. Silveira - *Porto Alegre, BRAZIL*  
 Advanced Stage III, histological type and age of patients affected by endometrial cancer are significant factors for high-risk neoplasia.

CASE REPORTS
--------------

<b>A new approach to vulvar squamous cell carcinoma: two-year follow-up of a case report</b>	51
E. Tartaglia, E.M. Messalli, M. Di Serio, M. Rotondi, G. Mainini, C. Di Serio - <i>Naples, ITALY</i> A case of an 88-year-old woman with advanced local vulvar cancer treated by modified application of the sentinel lymph node procedure is reported.	
<b>Primary peritoneal borderline tumour: report of an unusual case</b>	54
D. Couto, F. Mota, T. Silva, C. de Oliveira - <i>Coimbra, PORTUGAL</i> A case of a primary peritoneal borderline tumour, a rare lesion, histologically indistinguishable from non-invasive peritoneal implants found in association with ovarian tumours of borderline malignancy is reported.	
<b>Increased AFP as an indicator of ovarian carcinoma and fetal kidney carcinoma - case report</b>	57
D. Filimonovic, M. Gojnic, Lj. Arsenijevic, N. Popovic, V. Dugalic - <i>Belgrade, SERBIA AND MONTENEGRO</i> A 26-year-old patient in her first pregnancy presented with a double pathology - borderline ovarian carcinoma and fetal kidney tumor. The patient was treated from both aspects.	
<b>Oncogynaecological quadruplicity - case report</b>	60
J. Záhumenský, D. Driák, M. Halaška, J. Österreicher, M. Korešová, B. Sehnal, M. Krčmář - <i>Kradec Králové, PRAGUE</i> A case of primary oncogynaecological quadruplicity is described for the first time.	
<b>Squamous cell carcinoma developing in a huge dermoid cyst of the ovary in an 80-year-old woman - case report</b>	63
A. Başgül, H. Gökaslan, Z.N. Kavak, N. Güdücü, F. Eren - <i>Belgrade, SERBIA AND MONTENEGRO</i> The clinical and pathological features, treatment modalities and prognosis of squamous cell carcinoma developing to mature cystic teratoma are described.	
<b>Fulminant course of metastatic liposarcoma after delivery - case report</b>	67
L. Rousková, B. Melichar, D.H. Nikolov, J. Cerman Jr., E. Havel, J. Meganvocá, H. Urminská, P. Jandík - <i>Králové, CZECH REPUBLIC</i> A rapidly progressing case of metastatic retroperitoneal liposarcoma diagnosed during the third trimester of pregnancy is presented.	
<b>Cervical and duodenal polyps and their malignant alterations - case report</b>	69
M. Gojnic, D. Filimonovic, Lj. Arsenijevic, N. Popovic, V. Dugalic, V. Jeremic, I. Tulic, G. Radonjic, M. Pervulov, R. Argirovic - <i>Belgrade, SERBIA AND MONTENEGRO</i> During routine examination of a 32-year-old patient, a cervical polyp was found and CIN III was confirmed by biopsy. Complete diagnoses and therapy were carried out and duodenal resection and conization were performed.	
<i>Book Review</i>	72

**ERRATA - CORRIGE****Benign cystic mesothelioma presenting as a huge pelvic mass - a case report**

A. Coskun, M.A. Guven, O. Ozdemir, H. Cirakli, S. Karakus - *Kahramanmaraş (TURKEY)*  
Vol. XXVII, n. 6, 2006, page 621

**Corrige: Summary** - Benign cystic mesothelioma is an extremely rare peritoneal tumor. It is reported in women of child-bearing age but also in males and needs a careful differential diagnosis between benign and malign neoplasia to choose the most adequate therapy. A 25-year-old female was treated in our clinic for a gigantic cystic mass (25 x 22 x 3 cm in diameter) containing many to cysts of different sizes. All tumoral markers were within normal range. Surgical treatment consisted of radical excision of the mass and the prognosis was good.